Sulfated saccharosan and application thereof

Abstract

The invention discloses a preparation process and application of sulfated saccharosan. The sulfated saccharosan is prepared by the following steps: (1) preparing saccharosan solution, lauroyl chloride solution and chlorosulfonic acid solution; (2) mixing the lauroyl chloride solution and the saccharosan solution, reacting at the temperature of 60-80 DEG C, and incubating at room temperature for 18 hours; (3) mixing the chlorosulfonic acid solution with the solution obtained in the step (2), reacting at the temperature of 60-80 DEG C, and incubating at room temperature for 18 hours; (4) regulating the pH value of the reaction solution in the step (3) to be neutral by using NaOH solution, distilling to remove the solvent, washing and dialyzing to remove impurities, and drying to obtain the sulfated saccharosan, wherein a molecular ratio of the lauroyl chloride to saccharosan is (1.2-3.6):1, and a molecular ratio of the chlorosulfonic acid to saccharosan is (0.5-2.0):1. When an oil-in-water adjuvant is prepared by using the sulfated saccharosan, the concentration of porcine circovirus type II specific antibodies IgG and antibody subclasses IgG1 and IgG2a can be obviously increased, and the activity is equivalent to that of an oil adjuvant. The sulfated saccharosan can effectively improve the antigen immunocompetence and is expected to serve as a novel oil-in-water adjuvant for development and application.

Description

technical field [0001] The invention belongs to the technical field of oil-in-water adjuvants, and in particular relates to sulfated polysucrose and its application. Background technique [0002] There are currently three formulations of oil emulsion vaccines: water-in-oil (W / O), water-in-oil-in-water (W / O / W) and oil-in-water (O / W). W / O has the strongest immune activity, but has severe side effects and difficult injection; W / O / W has strong immune activity, but has poor thermal stability and short shelf life; O / W has little or no toxic and side effects, and good thermal stability , but the immune activity is weak. MF59 is the first O / W dosage form adjuvant to be commercially applied, and the human influenza vaccine prepared with it has been marketed in Europe and the United States. The oil of the adjuvant is squalene, which has the advantages of safety, minimal toxic and side effects, etc., and the surfactant is Tween and Spin series products. However, the immune activity ...

AI Technical Summary

Problems solved by technology

However, the immune activity of this adjuvant is relatively weak, it can only help induce a weak immune response, and it cannot meet the quality requirements of veterinary vaccines

In addition, squalene (or its analog squalane) is expensive, and it is difficult to be widely used in veterinary vaccine products

The French SEPPIC company used white oil instead of squalene and developed an O / W adjuvant (ISA15A VG) with Tween and Spin series products as surfactants, but it failed to achieve commercial application because of its weak immune activity.

Images